10X GENOMICS, INC., DEF 14A filed on 4/14/2025
Proxy Statement (definitive)
v3.25.1
Cover
 12 Months Ended
Dec. 31, 2024
Document Information [Line Items]  
Document Type DEF 14A
Amendment Flag false
Entity Information [Line Items]  
Entity Registrant Name 10x Genomics, Inc.
Entity Central Index Key 0001770787
v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Year
Summary Compensation Table Total for PEO1
($)
Compensation Actually Paid to PEO1,2,3
($)
Average Summary Compensation Table Total for Non-PEO NEOs1
($)
Average Compensation Actually Paid to Non-PEO NEOs1,2,3
($)
Value of Initial Fixed $100 Investment based on:4
Net Income
($ Millions)		Stock Price⁵
TSR
($)		Peer Group TSR
($)
20247,929,349 (21,169,246)4,399,950 (4,682,313)18.83 118.20 (183)14.36 
20238,286,049 17,348,412 3,397,530 7,387,885 73.39 118.87 (255)55.96 
202218,805,294 (14,310,774)9,376,988 (3,497,039)47.79 113.65 (166)36.44 
202111,700,985 20,812,842 4,979,234 9,325,452 195.36 126.45 (58)148.96 
202010,882,717 55,278,526 6,508,594 25,404,160 185.70 126.42 (543)141.6 
        
Company Selected Measure Name stock price        
Named Executive Officers, Footnote Serge Saxonov was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
20202021202220232024
Justin J. McAnearJustin J. McAnearJustin J. McAnearJustin J. McAnearAdam S. Taich
Benjamin J. HindsonBenjamin J. HindsonBenjamin J. HindsonBenjamin J. HindsonBenjamin J. Hindson
Ruth De BackerEric S. WhitakerEric S. WhitakerEric S. WhitakerEric S. Whitaker
Bradford J. CrutchfieldBradford J. CrutchfieldJames WilburJames WilburJustin J. McAnear
        
Peer Group Issuers, Footnote The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Composite Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotechnology Composite Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.        
PEO Total Compensation Amount $ 7,929,349 $ 8,286,049 $ 18,805,294 $ 11,700,985 $ 10,882,717
PEO Actually Paid Compensation Amount $ (21,169,246) 17,348,412 (14,310,774) 20,812,842 55,278,526
Adjustment To PEO Compensation, Footnote Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
Year
Summary Compensation Table Total for
Serge Saxonov
($)
Exclusion of Stock Awards and Option Awards
for Serge Saxonov
($)
Inclusion of
Equity Values for
Serge Saxonov
($)
Compensation Actually
Paid to Serge Saxonov
($)
20247,929,349 (6,979,037)(22,119,558)(21,169,246)
Year
Average Summary Compensation Table
Total for Non-PEO NEOs
($)
Average Exclusion
of Stock Awards and Option Awards for
Non-PEO NEOs
($)
Average Inclusion
of Equity Values for
Non-PEO NEOs
($)
Average Compensation Actually Paid to
Non-PEO NEOs
($)
20244,399,950 (3,941,881)(5,140,382)(4,682,313)
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
YearYear-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Serge Saxonov
($)		Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Serge Saxonov
($)		Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Serge Saxonov
($)		Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Serge Saxonov
($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Serge Saxonov
($)		Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Serge Saxonov
($)
Total - Inclusion of Equity
Values for
Serge Saxonov
($)
20241,238,422 (21,420,238)334,582 (2,272,324)— — (22,119,558)
YearAverage Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs
($)		Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs
($)		Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs
($)		Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs
($)		Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs
($)		Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs
($)		Total - Average Inclusion of
Equity Values for Non-PEO NEOs
($)
20241,331,283 (3,847,527)223,140 (1,186,393)(1,660,885)— (5,140,382)
        
Non-PEO NEO Average Total Compensation Amount $ 4,399,950 3,397,530 9,376,988 4,979,234 6,508,594
Non-PEO NEO Average Compensation Actually Paid Amount $ (4,682,313) 7,387,885 (3,497,039) 9,325,452 25,404,160
Adjustment to Non-PEO NEO Compensation Footnote Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
Year
Summary Compensation Table Total for
Serge Saxonov
($)
Exclusion of Stock Awards and Option Awards
for Serge Saxonov
($)
Inclusion of
Equity Values for
Serge Saxonov
($)
Compensation Actually
Paid to Serge Saxonov
($)
20247,929,349 (6,979,037)(22,119,558)(21,169,246)
Year
Average Summary Compensation Table
Total for Non-PEO NEOs
($)
Average Exclusion
of Stock Awards and Option Awards for
Non-PEO NEOs
($)
Average Inclusion
of Equity Values for
Non-PEO NEOs
($)
Average Compensation Actually Paid to
Non-PEO NEOs
($)
20244,399,950 (3,941,881)(5,140,382)(4,682,313)
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
YearYear-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Serge Saxonov
($)		Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Serge Saxonov
($)		Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Serge Saxonov
($)		Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Serge Saxonov
($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Serge Saxonov
($)		Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Serge Saxonov
($)
Total - Inclusion of Equity
Values for
Serge Saxonov
($)
20241,238,422 (21,420,238)334,582 (2,272,324)— — (22,119,558)
YearAverage Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs
($)		Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs
($)		Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs
($)		Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs
($)		Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs
($)		Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs
($)		Total - Average Inclusion of
Equity Values for Non-PEO NEOs
($)
20241,331,283 (3,847,527)223,140 (1,186,393)(1,660,885)— (5,140,382)
        
Compensation Actually Paid vs. Total Shareholder Return
3243
        
Compensation Actually Paid vs. Net Income
3573
        
Compensation Actually Paid vs. Company Selected Measure
3932
        
Total Shareholder Return Vs Peer Group
3243
        
Tabular List, Table
Stock Price
Revenue
        
Total Shareholder Return Amount $ 18.83 73.39 47.79 195.36 185.70
Peer Group Total Shareholder Return Amount 118.20 118.87 113.65 126.45 126.42
Net Income (Loss) $ (183,000,000) $ (255,000,000) $ (166,000,000) $ (58,000,000) $ (543,000,000)
Company Selected Measure Amount 14.36 55.96 36.44 148.96 141.6
PEO Name Serge Saxonov        
Additional 402(v) Disclosure The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized or received by the Company’s Non-PEO NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote (3) below.We determined stock price to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024. The amounts in the column represent the closing price on the last trading day of the listed year.        
Measure:: 1          
Pay vs Performance Disclosure          
Name Stock Price        
Measure:: 2          
Pay vs Performance Disclosure          
Name Revenue        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (6,979,037)        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (22,119,558)        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,238,422        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (21,420,238)        
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 334,582        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,272,324)        
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,941,881)        
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (5,140,382)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,331,283        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,847,527)        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 223,140        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,186,393)        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,660,885)        
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 0        
v3.25.1
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2024
Award Timing Disclosures [Line Items]  
Award Timing MNPI Disclosure
While we have not granted any stock options to NEOs since 2023, grants of options to purchase our common stock, including for our NEOs, are generally based upon a predetermined schedule each year as a part of the annual compensation process described in the “Equity Awards” section above. If annual long-term incentive compensation is determined to be appropriate, our board, the compensation committee or applicable designee approves any annual grants of equity awards, which can include stock options, for continuing employees in the first fiscal quarter commensurate with the prescheduled board and committee meetings. The grant dates of stock options are generally selected so as not to be within a short period of time, as described in the SEC’s Staff Accounting Bulletin 120 (“SAB 120”), prior to the release of MNPI such as on Forms 8-K, 10-Q or 10-K. Grants of stock options may occur at other times during the year due to business needs, such as for a newly hired employees or officers or newly appointed board members, though our current compensation program does not include stock options. The board, compensation committee or applicable designee does not anticipate the timing of disclosure of MNPI when determining the timing and terms of such awards, and we do not time the release of MNPI for the purpose of affecting the value of executive compensation .Exercise prices of stock options are based on the closing price of the underlying common stock on the grant date, subject to the applicable rules for non-qualified stock options and incentive stock options under the 2019 Plan. Vesting dates for stock options typically follow a standard monthly cadence and are not timed to anticipate the release of MNPI.
There were no grants of options to our NEOs within four business days before or one business day after the release of MNPI on Forms 8-K, 10-Q or 10-K in 2024. As such, no table of such option grants is presented under Item 402(x) of Regulation S-K.
Award Timing Method While we have not granted any stock options to NEOs since 2023, grants of options to purchase our common stock, including for our NEOs, are generally based upon a predetermined schedule each year as a part of the annual compensation process described in the “Equity Awards” section above. If annual long-term incentive compensation is determined to be appropriate, our board, the compensation committee or applicable designee approves any annual grants of equity awards, which can include stock options, for continuing employees in the first fiscal quarter commensurate with the prescheduled board and committee meetings. The grant dates of stock options are generally selected so as not to be within a short period of time, as described in the SEC’s Staff Accounting Bulletin 120 (“SAB 120”), prior to the release of MNPI such as on Forms 8-K, 10-Q or 10-K. Grants of stock options may occur at other times during the year due to business needs, such as for a newly hired employees or officers or newly appointed board members, though our current compensation program does not include stock options. The board, compensation committee or applicable designee does not anticipate the timing of disclosure of MNPI when determining the timing and terms of such awards, and we do not time the release of MNPI for the purpose of affecting the value of executive compensation .Exercise prices of stock options are based on the closing price of the underlying common stock on the grant date, subject to the applicable rules for non-qualified stock options and incentive stock options under the 2019 Plan. Vesting dates for stock options typically follow a standard monthly cadence and are not timed to anticipate the release of MNPI.
Award Timing Predetermined true
Award Timing MNPI Considered false
Award Timing, How MNPI Considered The grant dates of stock options are generally selected so as not to be within a short period of time, as described in the SEC’s Staff Accounting Bulletin 120 (“SAB 120”), prior to the release of MNPI such as on Forms 8-K, 10-Q or 10-K. Grants of stock options may occur at other times during the year due to business needs, such as for a newly hired employees or officers or newly appointed board members, though our current compensation program does not include stock options. The board, compensation committee or applicable designee does not anticipate the timing of disclosure of MNPI when determining the timing and terms of such awards, and we do not time the release of MNPI for the purpose of affecting the value of executive compensation .
MNPI Disclosure Timed for Compensation Value false
v3.25.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true